APA (7th ed.) Citation

Hamid, O., Hassel, J. C., Shoushtari, A. N., Meier, F., Bauer, T. M., Salama, A. K. S., . . . Middleton, M. R. (2023). Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: A phase 1 study. Journal for ImmunoTherapy of Cancer, 11(6), . https://doi.org/10.1136/jitc-2023-006747

Chicago Style (17th ed.) Citation

Hamid, Omid, et al. "Tebentafusp in Combination with Durvalumab And/or Tremelimumab in Patients with Metastatic Cutaneous Melanoma: A Phase 1 Study." Journal for ImmunoTherapy of Cancer 11, no. 6 (2023). https://doi.org/10.1136/jitc-2023-006747.

MLA (9th ed.) Citation

Hamid, Omid, et al. "Tebentafusp in Combination with Durvalumab And/or Tremelimumab in Patients with Metastatic Cutaneous Melanoma: A Phase 1 Study." Journal for ImmunoTherapy of Cancer, vol. 11, no. 6, 2023, https://doi.org/10.1136/jitc-2023-006747.